Cargando…
Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: a real−world retrospective study
OBJECTIVES: The treatment of locally advanced oral or oropharyngeal squamous cell carcinoma (LAOOPSCC) is surgery and radiotherapy or chemoradiotherapy but with unsatisfactory survival rate. Neoadjuvant programmed death-1 (PD-1) therapy are being used in several clinical trials. Therefore, in this r...
Autores principales: | Wu, Wen-Jie, Liu, Qian, An, Pu-Gen, Wang, Lin, Zhang, Jian-Yun, Chen, Yan, Zhang, Tong, Zhang, Jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685444/ https://www.ncbi.nlm.nih.gov/pubmed/38035079 http://dx.doi.org/10.3389/fimmu.2023.1282629 |
Ejemplares similares
-
Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort
por: Jiang, Qi, et al.
Publicado: (2023) -
Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study
por: He, Wenwu, et al.
Publicado: (2022) -
Pathological complete response to neoadjuvant tislelizumab plus chemotherapy in stage IIIB small cell lung cancer: A case report and literature review
por: Zhou, Nan, et al.
Publicado: (2023) -
Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer
por: Zhang, Baihua, et al.
Publicado: (2023) -
Pathologic complete response after neoadjuvant tislelizumab and chemotherapy for Pancoast tumor: A case report
por: Tang, Wen‐Fang, et al.
Publicado: (2021)